CN101460194B - 用于癌症治疗的粘液瘤病毒突变体 - Google Patents

用于癌症治疗的粘液瘤病毒突变体 Download PDF

Info

Publication number
CN101460194B
CN101460194B CN2007800202887A CN200780020288A CN101460194B CN 101460194 B CN101460194 B CN 101460194B CN 2007800202887 A CN2007800202887 A CN 2007800202887A CN 200780020288 A CN200780020288 A CN 200780020288A CN 101460194 B CN101460194 B CN 101460194B
Authority
CN
China
Prior art keywords
myxoma virus
protein
activity
myxoma
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800202887A
Other languages
English (en)
Chinese (zh)
Other versions
CN101460194A (zh
Inventor
约翰·W·巴雷特
格兰特·麦克法登
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Robarts Research Institute
Original Assignee
Robarts Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Robarts Research Institute filed Critical Robarts Research Institute
Publication of CN101460194A publication Critical patent/CN101460194A/zh
Application granted granted Critical
Publication of CN101460194B publication Critical patent/CN101460194B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/275—Poxviridae, e.g. avipoxvirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24032—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24061—Methods of inactivation or attenuation
    • C12N2710/24062—Methods of inactivation or attenuation by genetic engineering
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24071—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN2007800202887A 2006-06-01 2007-06-01 用于癌症治疗的粘液瘤病毒突变体 Expired - Fee Related CN101460194B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80364006P 2006-06-01 2006-06-01
US60/803,640 2006-06-01
PCT/US2007/070219 WO2007143548A2 (en) 2006-06-01 2007-06-01 Myxoma virus mutants for cancer treatment

Publications (2)

Publication Number Publication Date
CN101460194A CN101460194A (zh) 2009-06-17
CN101460194B true CN101460194B (zh) 2013-08-14

Family

ID=38802246

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800202887A Expired - Fee Related CN101460194B (zh) 2006-06-01 2007-06-01 用于癌症治疗的粘液瘤病毒突变体

Country Status (12)

Country Link
US (3) US8512713B2 (enExample)
EP (3) EP3254694A1 (enExample)
JP (4) JP2009538935A (enExample)
KR (1) KR20090014364A (enExample)
CN (1) CN101460194B (enExample)
AU (1) AU2007256754B2 (enExample)
CA (2) CA2652228C (enExample)
IL (1) IL195297A (enExample)
MX (1) MX2008015265A (enExample)
NZ (1) NZ572893A (enExample)
WO (1) WO2007143548A2 (enExample)
ZA (1) ZA200809769B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007256754B2 (en) 2006-06-01 2012-11-29 Robarts Research Institute Myxoma virus mutants for cancer treatment
FR2946536B1 (fr) * 2009-06-11 2011-07-29 Agronomique Inst Nat Rech Utilisation d'une souche attenuee de myxoma virus comme oncolytique
US12128099B2 (en) 2018-05-25 2024-10-29 Bioventures, Llc Myxoma virus compositions and methods of use
EP3846829A4 (en) * 2018-09-05 2022-09-14 Arizona Board of Regents on behalf of Arizona State University ONCOLYTIC VIRUS PLATFORM FOR THE TREATMENT OF HEMATOLOGICAL CANCER
WO2020106880A1 (en) 2018-11-20 2020-05-28 Bioventures, Llc Cells for the production of viruses and methods of using the same

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ518945A (en) 1997-10-09 2007-03-30 Wellstat Biologics Corp Treatment of neoplasms with viruses
ES2153284B1 (es) 1998-06-10 2001-09-01 Fundacion Para El Estudio Y De Nuevo virus recombinante de mixoma atenuado y su uso en la preparacion de vacunas mixtas contra la mixomatosis y la enfermedad hemorragica de los conejos.
AU4246900A (en) 1999-04-15 2000-11-02 Pro-Virus, Inc. Treatment of neoplasms with viruses
EP1200595A2 (en) 1999-07-12 2002-05-02 Viron Therapeutics, Inc. Myxoma virus genes for immune modulation
WO2001087324A1 (en) 2000-05-17 2001-11-22 Viron Therapeutics, Inc. Compositions and methods for promoting immunosuppression
DE60209345T2 (de) * 2001-03-08 2006-08-03 Akzo Nobel N.V. Leporipox-basierende vektorvakzine
US7582614B2 (en) * 2003-03-07 2009-09-01 Robarts Research Institute Use of myxoma virus for the therapeutic treatment of cancer and chronic viral infection
NZ550430A (en) 2004-04-27 2009-06-26 Wellstat Biologics Corp Cancer treatment using viruses and camptothecins
DK2388315T3 (da) * 2005-03-07 2014-08-25 Univ Western Ontario Anvendelse af et myxomvirus, som ikke eksprimerer funktionelt M135R, til terapeutisk behandling
WO2007143545A2 (en) 2006-06-01 2007-12-13 Robarts Research Institute Tnf signaling in myxoma virus treatments
AU2007256754B2 (en) 2006-06-01 2012-11-29 Robarts Research Institute Myxoma virus mutants for cancer treatment
WO2007147118A1 (en) 2006-06-16 2007-12-21 Robarts Research Institute Infection of cells with myxoma virus requires akt activation

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cameron,C.等.m63R [Myxoma virus]GenBank: AAF14951.1.《NCBI-GenBank》.2005, *

Also Published As

Publication number Publication date
US9980994B2 (en) 2018-05-29
JP2013100370A (ja) 2013-05-23
EP2021023A2 (en) 2009-02-11
IL195297A (en) 2015-04-30
KR20090014364A (ko) 2009-02-10
MX2008015265A (es) 2008-12-12
CN101460194A (zh) 2009-06-17
US20110158945A1 (en) 2011-06-30
AU2007256754A1 (en) 2007-12-13
EP2457584A1 (en) 2012-05-30
US8512713B2 (en) 2013-08-20
JP2017008105A (ja) 2017-01-12
CA2951453A1 (en) 2007-12-13
EP2457584B1 (en) 2017-08-09
US20130336930A1 (en) 2013-12-19
AU2007256754B2 (en) 2012-11-29
US20160136212A1 (en) 2016-05-19
JP2009538935A (ja) 2009-11-12
ZA200809769B (en) 2009-07-29
EP3254694A1 (en) 2017-12-13
JP5665899B2 (ja) 2015-02-04
EP2021023A4 (en) 2010-08-11
WO2007143548A2 (en) 2007-12-13
CA2652228C (en) 2017-07-11
NZ572893A (en) 2011-06-30
CA2652228A1 (en) 2007-12-13
IL195297A0 (en) 2009-08-03
WO2007143548A3 (en) 2008-09-25
JP2015044878A (ja) 2015-03-12

Similar Documents

Publication Publication Date Title
Takahashi et al. Live vaccine used to prevent the spread of varicella in children in hospital
Olson et al. CD8 T cells inhibit respiratory syncytial virus (RSV) vaccine-enhanced disease
Gao et al. Newcastle disease virus RNA-induced IL-1β expression via the NLRP3/caspase-1 inflammasome
US9987315B2 (en) Use of a combination of Myxoma virus and rapamycin for therapeutic treatment
CN101460194B (zh) 用于癌症治疗的粘液瘤病毒突变体
Duan et al. Antiviral effects of ergosterol peroxide in a pig model of porcine deltacoronavirus (PDCoV) infection involves modulation of apoptosis and tight junction in the small intestine
Baxter et al. Glutamine antagonist-mediated immune suppression decreases pathology but delays virus clearance in mice during nonfatal alphavirus encephalomyelitis
Ji et al. Neonatal murine model of coxsackievirus A2 infection for the evaluation of antiviral therapeutics and vaccination
Zhu et al. Biphasic activation of PI3K/Akt and MAPK/Erk1/2 signaling pathways in bovine herpesvirus type 1 infection of MDBK cells
Chang et al. Broad protection with an inactivated vaccine against primary-isolated lethal enterovirus 71 infection in newborn mice
Carr et al. Growth of a neuroinvasive strain of bluetongue virus in suckling mice
Kowalik et al. Hepatitis associated with parvovirus B19 infection in a 12-year-old-boy. Case report
Scheicher Oncolytic Virotherapy of Neuroendocrine Neoplasms with oncolytic measles vaccine virus
Dika-Haxhirexha et al. Abdominal disturbances in children with Covid-19
CN101082042A (zh) 人工改造的缺陷型人3型腺病毒的应用
Bravo Characterization of the vaccinia virus ankyrin repeat protein K1 on NF-κB inhibition and its contributions to viral pathogenesis
Parira et al. Histone H4 modification landscape due to chronic alcohol treatment in human monocyte-derived dendritic cells (MDDCs)
Jeyaretna The oncolytic herpes simplex virus G47? as a therapeutic agent against the glioma stem cell sub-population of glioblastomas
Costenbader et al. Monthly Archives: May 2017
Deresinski Treatment of Smallpox with lmatinab Mesylate.
Price III The Role of Cytomegalovirus in Glioblastoma and Rhabdomyosarcoma
HK1163175B (en) Use of a myxoma virus that does not express functional m135r for therapeutic treatment

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20130814

Termination date: 20210601